Analytical Data
-
Gene name
PLCg1
- Application
-
Alternative Names
NCKAP3; PLC-G1; PLC-II; PLC1; PLC148; PLCgamma1; 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1; Phosphoinositide phospholipase C-gamma-1
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P19174
-
Expression Region
Ser1091~Leu1290
-
Molecular Weight
27kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
PLCg1, or phospholipase C-gamma 1, is a crucial enzyme that plays a significant role in various intracellular signaling pathways, particularly in processes related to cell differentiation, proliferation, and apoptosis. It is involved in pathways activated by growth factor receptors and plays a pivotal role in the biology of immune cells and neuronal signaling. Research into PLCg1 has gained momentum due to its association with various diseases, including cancer and autoimmune disorders. The enzyme is activated through interactions with membrane receptors, leading to the generation of inositol trisphosphate and diacylglycerol, which in turn mobilize intracellular calcium and activate protein kinase C pathways. Dysregulation of PLCg1 activity can contribute to aberrant cell signaling and tumorigenesis, making it an attractive target for therapeutic intervention. Scientists have been focusing on the structural and functional characterization of PLCg1 recombinant proteins to better understand their roles and potential as drug targets. By utilizing recombinant DNA technology, researchers can produce PLCg1 in larger quantities and study its properties, interactions with other proteins, and regulatory mechanisms in detail, aiming to uncover novel approaches for treating diseases linked to this enzyme. The exploration of PLCg1 in disease contexts holds promise for developing targeted therapies and improving our understanding of cell signaling dynamics, ultimately contributing to advances in biomedical research and clinical applications.
